Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1745-1761

  Migliore, Mattia M ^a   Vyas, Tushar K ^a   Campbell, Robert B ^a   Amiji, Mansoor M ^a   Waszczak, Barbara L ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Blood brain barrier; Cationic liposomes; Intranasal delivery; Ovalbumin; Protein therapeutics

Indexed keywords

LIPOSOME; NANOPARTICLE; OVALBUMIN;

AQUEOUS SOLUTION; ARTICLE; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; INTESTINE; INTRANASAL DRUG ADMINISTRATION; MESENCEPHALON; NONHUMAN; PROTEIN DETERMINATION; PROTEIN TRANSPORT; RAT; STOMACH;

EID: 77949793045     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21939     Document Type: Article

References (66)

1. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Simpson LC. 1994. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266:1062-1064.
2. Alberch J, Perez-Navarro E, Canals JM. 2004. Neurotrophic factors in Huntington's disease. Prog Brain Res 146:195-229.
3. Fernandez-Espejo E. 2004. Pathogenesis of Parkinson's disease: Prospects of neuroprotective and restorative therapies. Mol Neurobiol 29:15-30.
4. Thorne RG, Frey WH II. 2001. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet 40:907-946.
5. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE. 2000. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 60:409-470.
6. Ikeda T, Xia XY, Xia YX, Ikenoue T, Han B, Choi BH. 2000. Glial cell line-derived neurotrophic factor protects against ischemia/hypoxia-induced brain injury in neonatal rat. Acta Neuropathol 100: 161-167.
7. Markus A, Patel TD, Snider WD. 2002. Neurotrophic factors and axonal growth. Curr Opin Neurobiol 12:523-531.
8. Gash DM, Zhang Z, Gerhardt G. 1998. Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44:S121-S125.
9. Granholm AC, Mott JL, Bowenkamp K, Eken S, Henry S, Hoffer BJ, Lapchak PA, Palmer MR, van HC, Gerhardt GA. 1997. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Exp Brain Res 116:29-38.
10. Pardridge WM. 2005. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2:3-14.
11. Kastin AJ, Akerstrom V, Pan W. 2003. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 340:239-241.
12. Vyas TK, Shahiwala A, Marathe S, Misra A. 2005. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2:165-175.
13. Illum L. 2004. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3-17.
14. Illum L. 2002. Nasal drug delivery: New developments and strategies. Drug Discov Today 7:1184-1189.
15. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH II. 2001. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187:91-97.
16. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH II. 2004. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151:66-77.
17. Thorne RG, Emory CR, Ala TA, Frey WH II. 1995. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692:278-282.
18. Merkus FW, van den Berg MP. 2007. Can nasal drug delivery bypass the blood-brain barrier?: Questioning the direct transport theory. Drugs R&D 8:133-144.
19. Merkus P, Guchelaar HJ, Bosch DA, Merkus FW. 2003. Direct access of drugs to the human brain after intranasal drug administration? Neurology 60:1669-1671.
20. van den Berg MP, Romeijn SG, Verhoef JC, Merkus FW. 2002. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods 116:99-107.
21. in't Veen JP, van den Berg MP, Romeijn SG, Verhoef JC, Merkus FW. 2005. Uptake of fluorescein isothiocyanate-labelled dextran into the CSF after intranasal and intravenous administration to rats. Eur J Pharm Biopharm 61:27-31.
22. van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW. 2004. Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: Studies in rats and comparison with a human study. Pharmaceut Res 21:799-802.
23. Van den Berg MP, Merkus P, Romeijn SG, Verhoef JC, Merkus FW. 2003. Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans. J Drug Target 11:325-331.
24. van den Berg MP, Verhoef JC, Romeijn SG, Merkus FW. 2004. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 58:131-135.
25. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. 2002. Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5:514-516.
26. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW. 1998. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1:35-44.
27. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH II. 2008. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152:785-797.
28. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496.
29. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. 2003. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255:87-97.
30. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A. 2005. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci 102:3811-3816.
31. Capsoni S, Giannotta S, Cattaneo A. 2002. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci 99:12432-12437.
32. Jin K, Xie L, Childs J, Sun Y, Mao XO, Logvinova A, Greenberg DA. 2003. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 53:405-409.
33. Alcalay RN, Giladi E, Pick CG, Gozes I. 2004. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361:128-131.
34. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. 2000. Activity-dependent neurotrophic factor: Intranasal administration of femtomolaracting peptides improve performance in a water maze. J Pharmacol Exp Therap 293:1091-1098.
35. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. 2005. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353-368.
36. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH II, Craft S. 2008. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13:323-331.
37. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. 2008. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
38. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. 2004. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29:1326-1334.
39. Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W. 2007. Intranasal insulin improves memory in humans: Superiority of insulin aspart. Neuropsychopharmacology 32:239-243.
40. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. 2007. Intranasal insulin to improve memory function in humans. Neuroendocrinology 86: 136-142.
41. Hallschmid M, Benedict C, Schultes B, Perras B, Fehm HL, Kern W, Born J. 2008. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 149:79-83.
42. Hallschmid M, Benedict C, Schultes B, Born J, Kern W. 2008. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obesity 32:275-282.
43. Reger MA, Craft S. 2006. Intranasal insulin administration: A method for dissociating central and peripheral effects of insulin. Drugs Today (Barc) 42:729-739.
44. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
45. Torchilin V. 1985. Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 2:65-115.
46. Yatvin M, Leikes P. 1982. Clinical prospects for liposomes. Med Phys 9:149-175.
47. Gregoriadis G. 1976. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 295:765-770.
48. Law SL, Huang KJ, Chou VH. 2003. Stability of desmopressin loaded in liposomes. J Liposome Res 13:269-277.
49. Gonda I. 1998. Mathematical modeling of deposition and disposition of drugs administered via the nose. Adv Drug Deliv Rev 29:179-184.
50. Law SL, Huang KJ, Chou HY. 2001. Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Rel 70:375-382.
51. Van Den Berg MP, Romeijn SG, Verhoef JC, Merkus FW. 2002. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods 116:99-107.
52. Gizurarson S, Bechgaard E, Hjortkjoer RK. 2006. Two intranasal administration techniques give two different pharmacokinetic results. Scand J Lab Anim Sci 33:35-38.
53. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. 2009. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 6:158-170.
54. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. 1999. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design. Proc Natl Acad Sci 96:4143-4148.
55. Gozes I, Morimoto B, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Conchav M, Vered K, Newton P, Aisen P, Matsuoka Y, van Dyck C, Thal L. 2005. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11:353-368.
56. Aubert-Pouessel A, Venier-Julienne MC, Clavreul A, Sergent M, Jollivet C, Montero-Menei CN, Garcion E, Bibby DC, Menei P, Benoit JP. 2004. In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Rel 95:463-475.
57. Yu H, Kim K. 2009. Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits. Int J Pharm 378:73-79.
58. Law SL, Huang KJ, Chou HY. 2001. Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Rel 70:375-382.
59. Ma YP, Ma MM, Ge S, Guo RB, Zhang HJ, FreyWH II, Xu GL, Liu XF. 2007. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res Bull 74:271-277.
60. Born J, Lange T, Kern W. 2002. Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5:514-516.
61. Zhao HM, Liu XF, Mao XW, Chen CF. 2004. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 19:257-261.
62. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF. 1998. Liposome-cell interactions in vitro: Effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37:12875-12883.
63. Friend D, Papahadjopoulos D, Debs R. 1996. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochem Biophys Acta 1278:41-50.
64. Briane D, Lesage D, Cao A, Coudert R, Lievre N, Salzmann JL, Taillandier E. 2002. Cellular pathway of plasmids vectorized by cholesterol-based cationic liposomes. J Histochem Cytochem 50: 983-991.
65. Graff CL, Pollack GM. 2005. Nasal drug administration: Potential for targeted central nervous system delivery. J Pharm Sci 94:1187-1195.
66. Kumagai AK, Eisenberg JB, Pardridge WM. 1987. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 262:15214-15219.